Effects of high-intensity focused ultrasound in the treatment of experimental neuroblastoma

doi:10.1016/0022-3468(92)90321-W

Journal of Pediatric Surgery

Volume 27, Issue 2, February 1992, Pages 246-251

https://doi.org/10.1016/0022-3468(92)90321-W Get rights and content

Abstract

This report evaluates the effect of high-intensity focused ultrasound (HIFU) on subcutaneous murine neuroblastoma C1300. HIFU treatment was administered with a focused 4-MHz quartz transducer with a peak intensity of 550 W/cm². In experiment 1, 60 animals with tumor were divided into four groups. Group I (n = 15) were controls; group II (n = 15) received adriamycin, 5 mg/kg intraperitoneally; group III (n = 15) received HIFU; and group IV (n = 15) received both adriamycin and HIFU. All the animals in groups I and II died of tumor by 35 days. Fifty-three percent ( $815$ ) of mice in group III and 80% ( $1215$ ) in group IV were cured with no evidence of tumor (NET) at 200 days. Log-rank statistics showed significant prolongation of survival in the groups III and IV as compared with groups I or II (P < .05). In experiment 2, 45 animals with tumor were divided into three groups. Group I (n = 15) were controls; group II (n = 15) received HIFU; and group III (n = 15) received repeated HIFU. The results showed 47% ( $715$ ) of mice in group II and 67% ( $1015$ ) in group III were NET at 200 days. Significant survival prolongation was achieved in groups II and III in comparison with group I (P < .05). In experiment 3, 90 mice received either tumor (n = 60) or saline (n = 30) inoculation in the left flank. On day 5, 45 mice with tumor were treated with HIFU (group I), while the other 15 mice with tumor (group II) had a sham procedure. Nineteen mice in group I were cured with NET (group IA) and 26 had persistent tumor (group IB). The 30 mice receiving saline (without tumor) were treated with either HIFU (group III, n = 15) or a sham procedure (group IV, n = 15). On day 26, all the animals received a second tumor challenge in the right flank. Reduced tumor growth following a second tumor challenge was demonstrated in group IA as compared with other groups (P < .001), implying a stimulation of host tumor immunity following curative HIFU treatment. The data suggest that HIFU may be an alternative modality for the treatment of unresectable neuroblastoma.

References (14)

JL Grosfeld et al.
Metastatic neuroblastoma: Factors influencing survival
J Pediatr Surg
(1978)
MM Ziegler et al.
Electrocoagulation induced immunity—An explanation for regression of neuroblastoma
J Pediatr Surg
(1980)
CJ McCormack et al.
Beneficial effects following carbon dioxide laser excision on experimental neurblastoma
J Pediatr Surg
(1989)
JL Grosfeld
Neuroblastoma: A 1990 overivew
Pediatr Surg Int
(1991)
JL Grosfeld
Neuroblastoma: Current concepts of management
Surg Rounds
(1987)
R Yang et al.
High intensity focused ultrasound in the treatment of experimental liver cancer
Arch Surg
(1991)
FJ Fry et al.
Threshold ultrasonic dosages for structure changes in the mammalian brain
J Acoust Soc Am
(1970)

There are more references available in the full text version of this article.

Cited by (86)

External stimuli-responsive nanomedicine for cancer immunotherapy
2023, Encyclopedia of Nanomaterials
Cancer immunotherapy has revolutionized clinical oncology and achieved remarkable success, through the use of immune checkpoint blockade antibodies and chimeric antigen receptor T cell therapy. Despite great promises, unsatisfactory response rates and off-target toxicities restrict widespread applications among cancer patients. The lack of successful clinical translation presents an imperative challenge in developing new immunotherapy agents. Nanoparticle-based drug delivery systems have been developed to increase the uptake of therapeutics by tumors and reduce therapeutics’ toxicities. External stimuli-activatable nanomedicine, therefore, holds considerable potential to improve the efficacy of cancer immunotherapy while minimizing side effects via tumor-specific accumulation, cell-specific targeting, and triggerable drug release profiles. We herein discuss how the emerging applications of various stimuli, including light, ultrasound, radiation, and magnetics, elicit anti-tumor immunity and elevate therapeutic performances.
Ultrasound-mediated immune regulation in tumor immunotherapy
2022, Materials Today Advances
Cancer immunotherapy, which enhances the body's immune response and inhibits immune escape to eliminate or combat tumors, holds great promise for cancer treatment. However, it still faces many challenges, such as low response rate and immune-related adverse events, which limit its clinical applications. Ultrasound, as a safe, effective and non-invasive technique, has been widely used in diagnostics and therapeutics of tumors. In recent years, many studies have confirmed that ultrasound can also mediate tumor immunotherapy. High intensity focused ultrasound can destroy tumor tissue and lead to the in situ production of tumor fragments at the same time, which can be used as antigens of the immune system to form in situ vaccines to induce a systemic immune response. The ultrasound-targeted microbubble destruction technique with microbubbles as the carrier mediates the targeted delivery of immunomodulatory adjuvants to tumor cells or immune cells. It can not only enhance the host immune response and improve immunotherapy efficacy, but also reduce the dosage of immunoregulatory adjuvants and side effects. Sonodynamic therapy can induce immunogenic cell death to elicit an immune response and the combination with immunotherapy can achieve higher therapeutic efficacy. In this review, research advances in ultrasound-mediated tumor immunotherapy are summarized, and the potential and challenges of its application are discussed.
Immunomodulatory effects of ablation therapy on tumors: Potentials for combination with immunotherapy
2020, Biochimica et Biophysica Acta - Reviews on Cancer
Citation Excerpt :
HIFU improves the infiltration of innate and adaptive immune cells into destroyed tumor tissues. Both T- and M-HIFU increase the number and cytotoxicity of CTLs, resulting in improved survival of mice [46–49]. They also contribute to the infiltration of CD11c + DCs [37].
As a promising area of tumor treatment, immunotherapies, such as immune checkpoint inhibitors, have been applied to various types of cancer. However, many patients do not respond to such therapies. Increasing application of tumor ablation therapy, a minimally invasive treatment, has been observed in the clinic. Although it can boost the anti-tumor immune response of patients in many ways, ablation alone is not sufficient to remove the tumor completely or stop tumor recurrence in the long term. Currently, there is emerging research focusing on ablation in combination with immunotherapy, aiming to confirm the therapeutic value of this treatment for cancer patients. Hence, in this article, we review the classification, guideline recommendations, and immunomodulatory effects of ablation therapy, as well as the pre-clinical and clinical research of this combination therapy.
High-Intensity Focused Ultrasound– and Radiation Therapy–Induced Immuno-Modulation: Comparison and Potential Opportunities
2017, Ultrasound in Medicine and Biology
Citation Excerpt :
Magnetic resonance–guided focused ultrasound surgery technology, which combines a HIFU beam and magnetic resonance imaging system, has the potential to locally achieve complete tumor cell destruction through thermal ablation, with great precision and minimal damage to adjacent tissues. By focusing a high-energy ultrasound beam to a well-defined target region, a local coagulative necrosis occurs due to the thermal dose released as the acoustic energy propagates through the focal tumor volume (Bastianpillai et al. 2015; ter Haar 1995; Wu et al. 2007a; Yang et al. 1992; Zhou 2011). Over the last 10 y, a growing number of clinical trials have examined HIFU treatment of both benign and malignant tumours of the liver, breast, pancreas, bone, connective tissue, thyroid, parathyroid, kidney and brain.
In recent years, high-intensity focused ultrasound (HIFU) has emerged as a new and promising non-invasive and non-ionizing ablative technique for the treatment of localized solid tumors. Extensive pre-clinical and clinical studies have evidenced that, in addition to direct destruction of the primary tumor, HIFU-thermoablation may elicit long-term systemic host anti-tumor immunity. In particular, an important consequence of HIFU treatment includes the release of tumor-associated antigens (TAAs), the secretion of immuno-suppressing factors by cancer cells and the induction of cytotoxic T lymphocyte (CTL) activity. Radiation therapy (RT) is the main treatment modality used for many types of tumors and about 50% of all cancer patients receive RT, often used in combination with surgery and chemotherapy. It is well known that RT can modulate anti-tumor immune responses, modifying micro-environment and stimulating inflammatory factors that can greatly affect cell invasion, bystander effects, radiation tissue complications (such as fibrosis), genomic instability and thus, intrinsic cellular radio-sensitivity. To date, various combined therapeutic strategies (such as immuno-therapy) have been performed in order to enhance RT success in treating locally advanced and recurrent tumors. Recent works suggested the combined use of HIFU and RT treatments to increase the tumor cell radio-sensitivity, in order to synergize the effects reaching the maximum results with minimal doses of ionizing radiation (IR). Here, we highlight the opposite immuno-modulation roles of RT and HIFU, providing scientific reasons to test, by experimental approaches, the use of HIFU immune-stimulatory capacity to improve tumor radio-sensitivity, to reduce the RT induced inflammatory response and to decrease the dose-correlated side effects in normal tissues.
Drug Delivery to the Brain via Focused Ultrasound
2015, Image-Guided Neurosurgery
In the last two decades, significant technological developments have enabled focused ultrasound (FUS) devices that can safely and precisely focus high intensity ultrasound beams through the intact human skull. The fine balance between tolerable skull heating and focal thermal doses capable of inducing coagulation necrosis, along with the integration with high-field MRI, have made noninvasive FUS ablation in the brain a reality that is already transforming functional neurosurgery. In addition to thermal effects, the mechanical effects associated with ultrasonically driven microbubbles in the brain vessels can provide a number of new therapies, including focal opening of the blood–brain barrier, enhancing gene therapies, and amplifying thrombolysis. At the same time, novel simulation tools and imaging approaches are enabling FUS treatment planning, monitoring, and assessment with unprecedented precision. With the success of the initial human trials, it is anticipated that this technology will continue to grow exponentially.
Ultrasound induced cancer immunotherapy
2014, Advanced Drug Delivery Reviews
Citation Excerpt :
Today HIFU has been applied in clinical studies to treat prostate cancer, breast cancer, kidney tumors, liver tumors, pancreas tumors and glioblastoma in the brain [46]. One of the early clues to the immune-stimulating potential of HIFU came from Yang and co-workers [47]. They treated mice with subcutaneous murine neuroblastoma C1300 with HIFU to ablate the tumors.
Recently, the use of ultrasound (US) has been shown to have potential in cancer immunotherapy. High intensity focused US destruction of tumors may lead to immunity forming in situ in the body by immune cells being exposed to the tumor debris and immune stimulatory substances that are present in the tumor remains.
Another way of achieving anti-cancer immune responses is by using US in combination with microbubbles and nanobubbles to deliver genes and antigens into cells. US leads to bubble destruction and the forces released to direct delivery of the substances into the cytoplasm of the cells thus circumventing the natural barriers. In this way tumor antigens and antigen-encoding genes can be delivered to immune cells and immune response stimulating genes can be delivered to cancer cells thus enhancing immune responses. Combination of bubbles with cell-targeting ligands and US provides an even more sophisticated delivery system whereby the therapy is not only site specific but also cell specific.
In this review we describe how US has been used to achieve immunity and discuss the potential and possible obstacles in future development.

View all citing articles on Scopus

^☆: Supported in part by American Cancer Society Institutional Grant No. 57-881-16, Atlanta, GA, and the Showalter Residuary Trust Fund, Indianapolis, IN.

^☆☆: Presented at the 22nd Annual Meeting of the American Pediatric Surgical Association, Lake Buena Vista, Florida, May 15–18, 1991.

View full text

Effects of high-intensity focused ultrasound in the treatment of experimental neuroblastoma☆,☆☆

Abstract

J Pediatr Surg

J Pediatr Surg

J Pediatr Surg

Neuroblastoma: A 1990 overivew

Pediatr Surg Int

Neuroblastoma: Current concepts of management

Surg Rounds

High intensity focused ultrasound in the treatment of experimental liver cancer

Arch Surg

Threshold ultrasonic dosages for structure changes in the mammalian brain

J Acoust Soc Am